<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> is a severe <z:e sem="disease" ids="C1535926" disease_type="Mental or Behavioral Dysfunction" abbrv="">neurodevelopmental disorder</z:e> with <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> and neurological deficits </plain></SENT>
<SENT sid="1" pm="."><plain>It results from a maternal deletion of human chromosome 15q11-13 containing two candidate genes E6-P ubiquitin-protein ligase (UBE3A) and <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor beta3 subunit (GABRB3), the latter of which has been also linked to <z:hpo ids='HP_0000717'>autism</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>To clarify the potential role of <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) beta3 subunit-containing inhibitory receptors in these disorders, we applied ligand autoradiography on brain sections from mice with inactivated GABRB3 or maternal UBE3A genes </plain></SENT>
<SENT sid="3" pm="."><plain>Binding of <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptor channel ([(35)S]t-butylbicyclophosphorothionate) and <z:chebi fb="13" ids="22720">benzodiazepine</z:chebi> ([(3)H]Ro 15-4513) site ligands was reduced in selected brain regions of the beta3-deficient mice as compared to controls, while the UBE3A-deficient mice failed to show reduced <z:chebi fb="3" ids="16865">GABA</z:chebi>(A) receptors </plain></SENT>
<SENT sid="4" pm="."><plain>The results, suggesting two different pathophysiological mechanisms, are in agreement with <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography results from <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e> patients of the corresponding genetic backgrounds </plain></SENT>
</text></document>